A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
AstraZeneca
EMD Serono
Groupe Oncologie Radiotherapie Tete et Cou
Inovio Pharmaceuticals
Arbeitsgemeinschaft medikamentoese Tumortherapie
Swedish Orphan Biovitrum
Tata Memorial Hospital
Sanofi
Vical